Sol-Gel Technologies Ltd. Share Price

Equities

SLGL

IL0011417206

Biotechnology & Medical Research

Market Closed - Nasdaq 02:00:01 27/04/2024 am IST 5-day change 1st Jan Change
0.8896 USD +3.32% Intraday chart for Sol-Gel Technologies Ltd. -5.36% -19.49%
Sales 2024 * 2.4M 200M Sales 2025 * 6.1M 509M Capitalization 24.78M 2.07B
Net income 2024 * -19M -1.58B Net income 2025 * -14M -1.17B EV / Sales 2024 * 10.3 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 4.06 x
P/E ratio 2024 *
-1.27 x
P/E ratio 2025 *
-2.17 x
Employees 36
Yield 2024 *
-
Yield 2025 *
-
Free-Float 34.83%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Sol-Gel Technologies Ltd.

1 day+3.32%
1 week-5.36%
Current month-9.23%
1 month-9.22%
3 months-25.87%
6 months-33.11%
Current year-19.49%
More quotes
1 week
0.86
Extreme 0.8608
0.99
1 month
0.79
Extreme 0.79
1.07
Current year
0.79
Extreme 0.79
1.58
1 year
0.79
Extreme 0.79
4.05
3 years
0.79
Extreme 0.79
14.50
5 years
0.00
Extreme 0
21.00
10 years
0.00
Extreme 0
21.00
More quotes
Managers TitleAgeSince
Founder 62 28/97/28
Director of Finance/CFO 56 01/17/01
Chief Operating Officer 48 01/10/01
Members of the board TitleAgeSince
Director/Board Member 55 26/23/26
Director/Board Member 50 13/18/13
Chairman 69 01/14/01
More insiders
Date Price Change Volume
26/24/26 0.8896 +3.32% 3,068
25/24/25 0.861 -6.41% 92,901
24/24/24 0.92 -0.56% 7,564
23/24/23 0.9252 -1.05% 8,832
22/24/22 0.935 -0.53% 15,611

Delayed Quote Nasdaq, April 27, 2024 at 02:00 am IST

More quotes
Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.8896 USD
Average target price
8 USD
Spread / Average Target
+799.28%
Consensus